Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat pain, addiction and psychiatric conditions and biological products to improve biodefense through potential medical counter-measures. Tonix's lead product candidate, TNX-102 SL, is in Phase 3 development as a bedtime treatment for fibromyalgia. Tonix is also developing TNX-102 SL as a bedtime treatment for agitation in Alzheimer's disease. TNX-601 (tianeptine oxalate) is in the pre-IND application stage, also for the treatment of major depressive disorder and PTSD, and is designed for daytime dosing. Tonix's lead biologic candidate, TNX-801, is a potential smallpox-preventing vaccine based on a live synthetic version of horsepox virus, currently in the pre-IND application stage.